



medicines
patent
pool

Meds PaL

THE MEDICINES PATENTS AND LICENCES DATABASE

www.medspal.org

1. Introduction to the Medicines Patent Pool
2. Background on MedsPaL
3. What patent information is included in MedsPaL?
4. What licensing and data exclusivity information is included in MedsPaL?
5. Demonstration
6. Next Steps



medicines
patent
pool


INTRODUCTION TO THE MEDICINES PATENT POOL

Founded in 2010 by  **Unitaid**
Innovation in Global Health

To increase **access** to new
treatments for HIV

And facilitate **innovation** e.g.
combinations and paediatrics


In 2015, expanded mandate to
Hepatitis C and **Tuberculosis**




MPP'S OBJECTIVES

- Accelerate the **availability** of generic versions of new treatments
- Enable the development of new **fixed-dose combinations (FDCs)** particularly when patents are held by different entities
- Encourage the development of **adapted formulations** for children or for specific developing country needs (e.g., heat stable formulations)





First patent pool in public health



MPP LICENCES GEOGRAPHICAL COVERAGE (BASED ON WORLD BANK CLASSIFICATIONS)

Product(s) Licensed	LIC	LMIC	UMIC	HIC	Undefined	Total
Abacavir (paed.)	31	53	31	5	1	121 +
Atazanavir	31	52	32	3	3	122 +
Bictegravir	30	48	25	9	4	116
Cobicistat	30	48	25	9	4	116
Daclatasvir	31	46	30	2	3	112 +
Dolutegravir (paed.)	31	53	31	5	1	121 +
Dolutegravir	31	53	6	2	0	92 +
Elvitegravir	30	42	17	8	3	100
Lopinavir/Ritonavir (paed.)	31	50	19	2	0	102
Lopinavir/Ritonavir (Africa)	26	17	10	2	2	57 +
Raltegravir (paed.)	31	50	9	2	0	92
Ravidasvir	1	9	9	-	-	19 #
Sutemizolid (global)	31	53	56	78	0	218
TDF	30	48	25	9	4	116
TAF	30	48	25	9	4	116

+ Additional countries may be able to benefit

Complements DNDi licence for a total of over 130 countries

MPP ACCOMPLISHMENTS



13 HIV medicines
and **1** HIV technology
platform licensed



130+
ongoing pharmaceutical
development projects



2 hepatitis C
direct-acting
antivirals



14.6 million
patient-years
and **5.3 billion** doses of
treatments delivered through
MPP's generic partners



1 tuberculosis
treatment



391 million
US dollars saved

EXPLORING EXPANSION INTO PATENTED ESSENTIAL MEDICINES

- The MPP is undertaking a **feasibility study** to assess the feasibility, desirability and potential public health impact of an MPP intervention on patented essential medicines
- A wide range of different **stakeholders** in governments, industry, academia and civil society are being consulted
- The study is being funded by the Swiss government
- The results of the study are expected to be available by Q2 2018



MPP IN RECENT UN STRATEGIES

UN Political Declaration on HIV/AIDS (2016), Paragraph 23:

“(...) welcome the broadening of the scope of work of the **Medicines Patent Pool**, hosted by UNITAID, to promote voluntary partnerships to address hepatitis C and tuberculosis, reflecting the importance of integrating the AIDS response into the broader global health agenda”



WHO Health Sector Strategy on HIV/AIDS 2016-21 (page 42)

“Strategies include fostering generic competition, including through, where appropriate, voluntary licences that include pro-access terms and conditions such as those negotiated by the **Medicines Patent Pool**”



UNAIDS 2016-21 Strategy (Page 83)


“Furthermore, UNAIDS will pursue additional collaboration with the **Medicines Patent Pool**, an initiative funded by UNITAID, to elaborate analyses on the patent landscape of HIV medicines and forecasting of newer HIV-related products.”





BACKGROUND ON MEDSPAL


- In order to prioritize medicines for in-licensing important to know which **HIV medicines** were patented where
- Through on-line searches and the **support of WIPO and many patent offices**, the MPP managed to obtain information for over 60 countries
- Many **requests for data** from public health stakeholders convinced us to make data public



Launched in April 2011 and regularly updated and expanded

Included patent status data for 24 HIV medicines in 88 countries

Most complete source of patent status data on HIV medicines in developing countries



Use Ctrl + click (Cmd + click on an Apple) or Shift + Click to select multiple variables. Click the button to expand/collapse the table, or scroll to see more countries. For more information about the database, including terms used, [see this useful history page](#). For the most up-to-date information on individual patents, consult [the local patent office](#). Download the latest available version of the database here: [Patent Status Table On Spreadsheet: 201312b1](#)

TBR / Variant	Patent Holder	Patent Application	Priority Number	Date of Expiration	Algeria	Algeria	Argentina	ARZPO	Armenia	Azerbaijan	Bahrain	Botswana	Burkina Faso and Madagascar	
Abacavir sulfate (ABC)	Wellcome (GSK)	WO9130231 + EP0434432	US 5889 371/001, 5889 045/001	June/Dec. 2010	No last updated Sept 2015	No preliminary	No last updated Jan. 2013	Expired (AP196) last updated Nov. 2013	No last updated May 2012	No last updated May 2012	No last updated Jan 2015	No last updated June 2012	No last updated May 2012	
In combination with Zidovudine (ZDV), Zalcitabine (ZTC) & Lamivudine (3TC)	GSK, VIV	WO201094130	US 2010 61/298,989	Jan. 2011	Filed (ALP/2515/274) Last updated Sept. 2015	Filed (OE120923) last updated May 2014	No last updated May 2014	Filed (APP9110064448) last updated Oct. 2014	Filed (EA301305883) last updated Jan 2015	Filed (EA301305883) last updated Jan 2015	Filed (EA301305883) last updated Jan 2015	No last updated May 2014	Filed last updated May 2014	
In combination with Lamivudine (3TC) & Zidovudine (ZDV)	Wellcome (GSK)	WO9330033	GB 9326493.5, GB 9326493.3	2016	No last updated Sept 2015	No preliminary	No last updated January 2015	Granted (AP622) last updated Oct. 2014	Granted (EA0006236) last updated Jan 2015	Granted (EA0006236) last updated Jan 2015	Granted (EA0006236) last updated Jan 2015	Granted (EA0006236) expires in March 2021 last updated Jan 2015	No last updated June 2013	Unknown preliminary
Composition for paediatric use	Wellcome (GSK)	WO9939691	GB 1998 9802472.2	2019	No last updated Sept 2015	Granted (DZ2767) Last updated April 2014 based on information provided by the patent holder	Granted (AR017485) last updated Jan. 2013	Granted (AP1312) last updated Oct. 2014	Granted (EA002916) last updated Jan 2015	Granted (EA002916) last updated Jan 2015	Granted (EA002916) last updated Jan 2015	No last updated June 2012	No last updated May 2012	
Emtricitabine aAT	Wellcome (GSK)	WO9823849	GB 1997 9709945.1	2018	No last updated Sept 2015	Granted (DZ2483) Last updated April 2014 based on information provided by the patent holder	Granted (AR015668, AR059326) last updated Jan. 2013	Granted (AP2009) last updated Oct. 2014	Granted (EA001809) last updated Jan 2015	Granted (EA001809) last updated Jan 2015	Granted (EA001809) last updated Jan 2015	Granted (EA001809) expires in May 2023 last updated Jan 2015	No last updated June 2012	No last updated May 2012
Atazanavir (ATV)	Novartis (BMS)	WO9740039	CH 1995 1810/NB, CH 1997 29/97/CH 1997 224/97	2017	No last updated Sept 2015	No last updated Nov. 2013	Granted (AR006720) last updated Jan. 2013	No last updated Nov. 2013	Lapsed (EA001794) last updated Jan 2015	Lapsed (EA001794) last updated Jan 2015	Lapsed (EA001794) last updated Jan 2015	No last updated June 2012	No last updated May 2012	
Bictegravir aAT	BMS	WO9935404	US 1998 60/071,868	2018	No last updated Sept 2015	No last updated Nov. 2013	Granted (AR014137) last updated Jan. 2013	No last updated Nov. 2013	No last updated Jan 2015	No last updated Jan 2015	No last updated Jan 2015	No last updated Jan 2015	No last updated June 2012	No last updated May 2012

FEEDBACK FROM STAKEHOLDERS (2012)



"The Medicines Patent Pool's Patent Status Database for Selected HIV Medicines takes an invaluable step towards furthering access to treatment of HIV/AIDS amassing information from numerous patent registries and jurisdictions into an easily navigable resource available to the public"

"The Medicines Patent Pool database is an essential impartial reference source for Global Fund Principal Recipients to understand the patent status of ARVs in their country - and it should be further expanded to include more countries."



"In the midst of a current patent regime that is at times not so transparent, this database is a great and valuable tool for players in the field, and one we regularly check as part of our procedures for determining a patent status. [It] ultimately allow[s] us to focus more of our energy into the actual delivery of HIV medicines to the ones who need it."

"The patent status database is an incredibly useful resource as it provides the most comprehensive pool of the available information on patent statuses, and combines this into one easy to use search engine."



- The new **WHO Global Health Sector Strategy for HIV (2016-2021)**, approved by all Member States, indicates that the WHO *“collaborates with the Medicines Patent Pool, which maintains a database on patent status...”*



- The **UNAIDS 2016-21 strategy** entitled “On the Fast-Track to End AIDS” states that *“UNAIDS will pursue additional collaboration with the Medicines Patent Pool, an initiative funded by UNITAID, to elaborate analyses on the patent landscape of HIV medicines...”*





MedsPaL

THE MEDICINES PATENTS & LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

In October 2016, MPP launches MedsPaL as the most comprehensive source of information on the patent and licensing status of medicines for HIV, TB and hepatitis C in low- and middle-income countries



Patent status data from over 110 low- and middle-income countries



Data exclusivity information from 15 countries



Covering approx. 70 medicines (over 130 formulations)



Information on all relevant licences in LMICs

www.medspal.org

KEY FEATURES OF MEDSPAL



Enables search by name of medicine, formulation, country, etc.




Key IP data in one place: patent status, licences, data exclusivity



Information for more than 110 low and middle income countries



Provides links to additional information



Regularly updated including automated updates for some patent applications



Enables users to download patent status data for further analysis




Possibility to sign up to receive information on new features and updates



WHAT INFORMATION IS INCLUDED IN MEDSPAL?

WHICH PRODUCTS ARE INCLUDED?


Patented medicines for the treatment of HIV, hepatitis C and tuberculosis that are (or were) included in WHO treatment guidelines



WHO HIV
Treatment
Guidelines



WHO Hepatitis C
Treatment
Guidelines



WHO MDR-TB
Treatment
Guidelines

NEW: EXPANDED TO INCLUDE OTHER PATENTED MEDICINES ON WHO ESSENTIAL MEDICINES LIST




WHO Model List
of Essential
Medicines (EML)

- Expanded **today** to include patented medicines on the WHO Essential Medicines List (WHO EML)
- In addition to HIV, HCV and TB, now patented cancer medicines also included
- Will be regularly updated as WHO EML is expanded

MedsPaL now includes a total of approximately 70 medicines with over 130 pharmaceutical formulations

HOW ARE PATENT FAMILIES IDENTIFIED?


Challenge: A simple patent search using a product name can yield hundreds of results and would not include the main patent claiming the molecule itself



US FDA Orange Book
(automated)



Health Canada
Patent Register
(automated)



Publicly available
licences (e.g.
MPP)



Published patent
landscapes (e.g.
WHO or UNITAID)

Approach: Patent families disclosed by patent holders to the USFDA and Health Canada Patent Registry. Supplemented with patent families disclosed in licences and in patent landscapes of reputable organizations.

Over 210 patent families were identified and included in MedsPaL

HOW IS NATIONAL/REGIONAL PATENT DATA OBTAINED?

Automated data feeds from the EPO are supplemented with data collected from individual patent offices through on-line searches, direct collaboration with patent offices and via local experts; patent holder disclosures and WIPO PatentScope.



*National
/Regional
Patent Offices*



*PATENT
HOLDER
DISCLOSURES*

Automatic data feeds
from Esp@acenet

Direct communication,
MOUs, on-line searches

National patent collections
on PatentScope

In licences or to
patent offices

MedsPaL includes patent status data on over 6,800 national patents or patent applications.

MOUs WITH NATIONAL/REGIONAL PATENT OFFICES



The MPP has signed collaboration agreements (MOUs) with 7 patent offices and looks forward to expanding its network of collaborating patent offices

Key objective: maintain data in MedsPaL as up to date as possible through collaboration with patent offices

Nature of the collaboration:

- MPP requests legal status information on up to 30 patent applications every year
- Request usually includes national patent application number or international patent application + priority number
- Patent offices provide legal status information for these patents
- MPP includes information in MedsPaL

Note: Where patent office already has a public database with legal status information, or provides this regularly to Espacenet, requests may be limited to clarifications



medicines
patent
pool

**WHAT LICENSING AND DATA
EXCLUSIVITY INFORMATION IS
INCLUDED IN MEDSPAL?**

WHAT INFORMATION ON LICENCES IS INCLUDED IN THE DATABASE?

Types of Licences

Licences negotiated by the
Medicines Patent Pool



Bilateral licences between
originators and generics



Commitments not to enforce
patents on a given product



Compulsory licences



Information in MedsPaL

Full information on the licences incl.
links to summaries and full text

Information on countries, products,
licensees (where public or provided by
patent holder for public disclosure)

Information on countries and products

Based on publicly available information

HOW IS INFORMATION ON DATA EXCLUSIVITY OBTAINED?

- **Data exclusivity:** Some LMICs have adopted regulations providing for data exclusivity (DE) in relation to the submission of pharmaceutical test data to regulatory authorities for approval of new medicines
- **Data on MedsPaL:** data from **15 countries** has been collected for HIV, TB and HCV medicines with expiry dates and will be supplemented further as data is gathered
- **Source of data:** National regulatory authorities (sometimes aided by patent office or local experts)
- **Other essential medicines:** Data on cancer medicines included in WHO EML is being collected for inclusion



medicines
patent
pool

DEMONSTRATION

www.medspal.org

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

[Add/Remove Columns ⚙](#)[Export Patent Data ↓](#)

- Free search by Keyword (e.g. patent number; brand name; country, etc.)

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[*Additional information and disclaimer*](#)

[Add/Remove Columns ⚙](#)[Export Patent Data ↓](#)

- Pre-determined search by Products (e.g. Abacavir 300mg)

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

[Add/Remove Columns ⚙](#)[Export Patent Data ↓](#)

- Pre-determined search by Countries (e.g. Chile, South Africa, Vietnam)





MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

Showing results 1 through 3 out of 3 total results

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/y)	
	Argentina	Bedaquiline 100 mg	Bedaquiline fumarate salt	Rejected	ARP070105442	31/01/2014
			Bedaquiline to treat MDR TB	Withdrawn	ARP050102200	20/10/2014
			Bedaquiline to treat latent TB	Withdrawn	ARP050105140	13/11/2014
			Bedaquiline compounds family	Granted	ARP030102655	24/07/2023
	Brazil	Bedaquiline 100 mg	Bedaquiline compounds family	Filed	BR0312927	18/07/2023
			Bedaquiline to treat MDR TB	Filed	BRPI0510414	24/05/2025
			Bedaquiline to treat latent TB	Filed	BRPI0506400	08/12/2025
			Bedaquiline process	Filed	BRPI0611166	22/05/2026
			Bedaquiline fumarate salt	Filed	BRPI0719693	03/12/2027
	Ecuador	Bedaquiline 100 mg	Bedaquiline compounds family	Not Filed		
			Bedaquiline to treat MDR TB	Not Filed		
	South Africa	Bedaquiline 100 mg	Bedaquiline compounds family	Granted	ZA200500680	24/01/2025
			Bedaquiline to treat MDR TB	Granted	ZA200609899	27/11/2026
			Bedaquiline to treat latent TB	Granted	ZA200705160	22/06/2027
			Bedaquiline process	Granted	ZA200710150	26/11/2027
			Bedaquiline fumarate salt	Granted	ZA200903907	04/06/2029





MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

Showing results 1 through 3 out of 3 total results

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/y)	
	Argentina	Bedaquiline 100 mg	Bedaquiline fumarate salt	Rejected	ARP070105442	31/01/2014
			Bedaquiline to treat MDR TB	Withdrawn	ARP050102200	20/10/2014
			Bedaquiline to treat latent TB	Withdrawn	ARP050105140	13/11/2014
			Bedaquiline compounds family	Granted	ARP030102655	24/07/2023
	Brazil	Bedaquiline 100 mg	Bedaquiline compounds family	Filed	BR0312927	18/07/2023
			Bedaquiline to treat MDR TB	Filed	BRPI0510414	24/05/2025
			Bedaquiline to treat latent TB	Filed	BRPI0506400	08/12/2025
			Bedaquiline process	Filed	BRPI0611166	22/05/2026
			Bedaquiline fumarate salt	Filed	BRPI0719693	03/12/2027
	Ecuador	Bedaquiline 100 mg	Bedaquiline compounds family	Not Filed		
			Bedaquiline to treat MDR TB	Not Filed		
	South Africa	Bedaquiline 100 mg	Bedaquiline compounds family	Granted	ZA200500680	24/01/2025
			Bedaquiline to treat MDR TB	Granted	ZA200609899	27/11/2026
			Bedaquiline to treat latent TB	Granted	ZA200705160	22/06/2027
			Bedaquiline process	Granted	ZA200710150	26/11/2027
			Bedaquiline fumarate salt	Granted	ZA200903907	04/06/2029

Patent Card ✕

Country:	South Africa
Patent Application Number:	ZA200500680
Patent Status:	Granted
Patent Application Date (dd/mm/yyyy):	24/01/2005
Expected Expiry Date (dd/mm/yyyy):	24/01/2025
Patent Description:	Bedaquiline compounds family
Invention Title:	Quinoline Derivatives And Their Use As Microbacterial Inhibitors
Patent Family Identification:	US FDA
Publication / Grant Number(s):	ZA200500680B
Priority Number(s):	US39871102
Patent Applicant(s):	Janssen Pharmaceutica N.V
PCT Related Application(s):	WO2004011436A1
Patent Status Source:	National Patent Office
Last Updated (dd/mm/yyyy):	05/10/2016

 Print
 Copy Link

Close

Keyword Search

Country	Product Name
Argentina	Bedaquiline 100 mg
Brazil	Bedaquiline 100 mg
Ecuador	Bedaquiline 100 mg

Expected Expiry Date (dd/mm/yyyy)
31/01/2014
20/10/2014
13/11/2014
24/07/2023
18/07/2023
24/05/2025
08/12/2025
22/05/2026
03/12/2027



medicines
patent
pool

EXAMPLE 2

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

Keyword Search

× Daclatasvir 60 mg



× India

× South Africa

Add/Remove Columns ⚙

Export Patent Data ↓

Showing result 1 out of 1 total results

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 India	Daclatasvir 60 mg	Daclatasvir compound family	Filed (opposed)	IN853/DELNP/09	09/08/2027
		Daclatasvir crystalline forms	Filed (opposed)	IN806/DELNP/2010	31/07/2028
		Daclatasvir intermediate manufacturing process	Filed (opposed)	IN3999/CHENP/2012	02/11/2030
Licence(s):					
MPP licence on daclatasvir (DCV)					
 South Africa	Daclatasvir 60 mg	Daclatasvir compound family	Granted	ZA200900962	09/08/2027
		Daclatasvir crystalline forms	Granted	ZA201000843	31/07/2028
Licence(s):					
MPP licence on daclatasvir (DCV)					

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

Keyword Search

× Daclatasvir 60 mg



× India

× South Africa

Add/Remove Columns ⚙

Export Patent Data ↓

Showing result 1 out of 1 total results

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 India	Daclatasvir 60 mg	Daclatasvir compound family	Filed (opposed)	IN853/DELNP/09	09/08/2027
		Daclatasvir crystalline forms	Filed (opposed)	IN806/DELNP/2010	31/07/2028
		Daclatasvir intermediate manufacturing process	Filed (opposed)	IN3999/CHENP/2012	02/11/2030
Licence(s):					
MPP licence on daclatasvir (DCV)					
 South Africa	Daclatasvir 60 mg	Daclatasvir compound family	Granted	ZA200900962	09/08/2027
		Daclatasvir crystalline forms	Granted	ZA201000843	31/07/2028
Licence(s):					
MPP licence on daclatasvir (DCV)					

Licence Card



Title: MPP licence on daclatasvir (DCV)

Type: MPP Licence

Licensor: Bristol-Myers Squibb

Countries: Afghanistan, Algeria, Angola, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Congo, Democratic Republic of the, Cook Islands, Costa Rica, Côte d'Ivoire, Cuba, Djibouti, Dominica, Dominican Republic, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Grenada, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iraq, Jamaica, Kenya, Kiribati, Korea, DPR of, Lao PDR, Lesotho, Liberia, Libya, Madagascar, Malawi, Maldives, Mali, Marshal Islands, Mauritania, Mauritius, Micronesia, Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Philippines, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Swaziland, Syrian Arab Republic, Tanzania, United Republic of, Timor-Leste, Togo, Tonga, Tunisia, Turkmenistan, Tuvalu, Uganda, Uzbekistan, Vanuatu, Vietnam, West Bank & Gaza, Yemen, Zambia, Zimbabwe [Hide last 102](#)

Licensee(s): Aurobindo, Beximco, Cadila Healthcare, Cipla, Emcure, Hetero, Laurus Labs, Mylan, Natco Pharma, Sandoz

Print

Copy Link

Close

Africa

Expected Expiry Date (dd/mm/yyyy)

09/08/2027

31/07/2028

02/11/2030

09/08/2027

31/07/2028

Keyword Search

Product Name Pat

clatasvir 60 Dac

Dac

Dac proc

licence(s):

PP licence on daclatas

clatasvir 60 Dac

Dac

Licence Card



SIGN UP FOR UPDATES

Title:	MPP licence on daclatasvir (DCV)
Type:	MPP Licence
Licensor:	Bristol-Myers Squibb
Countries:	Afghanistan, Algeria, Angola, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Congo, Democratic Republic of the, Cook Islands, Costa Rica, Côte d'Ivoire, Cuba, Djibouti, Dominica, Dominican Republic, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Grenada, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iraq, Jamaica, Kenya, Kiribati, Korea, DPR of, Lao PDR, Lesotho, Liberia, Libya, Madagascar, Malawi, Maldives, Mali, Marshal Islands, Mauritania, Mauritius, Micronesia, Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Philippines, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Swaziland, Syrian Arab Republic, Tanzania, United Republic of, Timor-Leste, Togo, Tonga, Tunisia, Turkmenistan, Tuvalu, Uganda, Uzbekistan, Vanuatu, Vietnam, West Bank & Gaza, Yemen, Zambia, Zimbabwe Hide last 102
Licensee(s):	Aurobindo, Beximco, Cadila Healthcare, Cipla, Emcure, Hetero, Laurus Labs, Mylan, Natco Pharma, Sandoz

Print

Copy Link

Close

Africa

**Expected Expiry Date
(dd/mm/yyyy)**

09/08/2027

31/07/2028

02/11/2030

09/08/2027

31/07/2028

From the licence card, users can access further information on MPP licences

This includes a summary of key features and full text of MPP licences

Links to information about other licences also included where available

ATAZANAVIR (ATV)

COMPANY: BRISTOL-MYERS SQUIBB

DATE: DECEMBER 2013



Bristol-Myers Squibb

In December 2013, the MPP announced an agreement with biopharmaceutical company Bristol-Myers Squibb to increase access to a key HIV medicine, atazanavir (ATV), part of the WHO-preferred second-line treatment for adults and children. In July 2017, the MPP signed an extension of its licence agreement to include 12 additional countries, namely, Algeria, Cook Islands, Egypt, Equatorial Guinea, Indonesia, Malaysia, Morocco, Niue, the Philippines, Tunisia, Ukraine and Vietnam. The licence allows generic manufacture of ATV for sale in **at least 122 countries** that together are home to 89% of people living with HIV in low- and middle-income countries.



– LICENCE AGREEMENT



– SUBLICENCE AGREEMENT - FORM



KEY
FEATURES



PRESS
RELEASE



CHAIRMAN'S
SUMMARY



ADVISORY GROUP
REPORT



COUNTRY
LIST

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[*Additional information and disclaimer*](#)

[Add/Remove Columns ⚙](#)[Export Patent Data ↓](#)

Showing result 1 out of 1

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
	Chile	Dolutegravir 50 mg	Dolutegravir compound	Not Filed	

Data Exclusivity:

Test data exclusivity until 20/11/2018

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

[Additional information and disclaimer](#)

[Add/Remove Columns ⚙](#)[Export Patent Data ↓](#)

Showing result 1 out of 1

Country	Product Name	Patent Description	Patent Status	Patent Application Number	Expected Expiry Date (dd/mm/yyyy)
 Chile	Dolutegravir 50 mg	Dolutegravir compound	Not Filed		

Data Exclusivity:

Test data exclusivity until 20/11/2018

*MedsPaL should not be considered a complete and authoritative source of patent information **and is not meant to provide a ‘freedom-to-operate’ analysis.** It only provides a snapshot at a particular point in time, based on the information that was available to the Medicines Patent Pool*

*Interested users are advised to **contact the relevant national/regional patent office**, or to consult local patent counsel, to obtain up to date information on any given patent application identified in MedsPaL*

*Users are also invited to submit information on any data that requires updating to the MPP at **medspal@medicinespatentpool.org***



medicines
patent
pool

NEXT STEPS

- Additional features will be added to MedsPaL over time including:
 - Possibility to visualize search results via maps and brief search reports on pre-defined queries
- Addition of additional patented EML medicines
- Establish collaboration with additional patent offices



ESTABLISH COLLABORATION WITH ADDITIONAL PATENT OFFICES

- MedsPaL is a public resource that is being widely used by the public health community. Its usefulness is directly linked to accuracy of the data
- Establishing formal collaborations with as many national patent offices is crucial to maintaining the data up to date
- MOUs have already been signed with 7 national/regional patent offices and more are under discussion

The MPP's HIV, TB and hepatitis C activities, including MedsPaL, are fully funded by **UNITAID**:



Funding provided by the **Swiss Agency for Development and Cooperation** (SDC) for MPP's feasibility study on the potential expansion of its licensing activities into patented essential medicines made the upgrade of MedsPaL to include other essential medicines possible.



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Agency for Development
and Cooperation SDC

Visit MedsPaL on:

www.MedsPaL.org

And sign up for updates!